GlassScriptPhysician profile
Aaron C Labove
NPI 1760933139
$4,415.78
in general payments reported to CMS, 2019-2025
25 companies · $915 in 2025
The $915 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $608 · 2022: $954 · 2023: $872 · 2024: $1,067 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $885.20 | 2021-2025 | |
| Boston Scientific Corporation | $574.53 | 2021-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Watchman |
| Amgen INC. | $479.99 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $471.07 | 2021-2025 | Cardiomems, Pressurewire |
| Merck Sharp & Dohme LLC | $377.67 | 2021-2025 | Verquvo, Lagevrio |
| Irhythm Technologies, INC. | $213.76 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Impulse Dynamics (USA) INC. | $203.11 | 2022-2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $187.33 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $164.21 | 2021-2024 | Nexletol, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $139.75 | 2021-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.01 | 2021-2025 | Lifevest |
| Biosense Webster, INC. | $83.76 | 2022-2024 | Carto 3 |
| Kestra Medical Technology Services, INC. | $75.94 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $70.74 | 2021-2022 | |
| Novo Nordisk INC | $65.50 | 2025 | Wegovy, Ozempic, Rybelsus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $61.29 | 2021-2022 | |
| Amarin Pharma, INC. | $48.69 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.53 | 2022-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $32.20 | 2021 | |
| Kaneka Medical America LLC | $27.16 | 2025 | Apheresis Machine |
| Medtronic, INC. | $26.12 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $22.78 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $17.83 | 2025 | |
| Ge Healthcare | $13.84 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Labove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.